To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
SemBiosys Issued Key U.S. Patent for the Production of Apolipoproteins in Plants
Read time: Less than a minute
SemBioSys Genetics Inc. has announced that the United States Patent and Trade Mark Office has granted the Company U.S. patent 7,786,352 entitled "Methods for the Production of Apolipoproteins in Transgenic Plants".
The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into mature plants which produce seeds that express apolipoprotein. This patent is key to successfully commercializing plant made and seed expressed Apo AI(Milano).
The intent of the Company's global patent strategy is to own exclusive rights to transgenic production of biosimilar drugs and novel drug candidates like Apo AI(Milano) in select plant and plant-seed lines and to be able to make such drugs in a scalable manner. In doing so, the Company believes it is rapidly becoming a highly attractive partner to large pharma partners looking to enter these markets with a differentiated and patent protected manufacturing cost structure.
A counterpart to the U.S. patent US 7,786,352 was issued in New Zealand and South Africa, and corresponding patents are pending in many jurisdictions worldwide including Europe, China, Japan, India, Eurasia, Brazil, Australia and Canada.
The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into mature plants which produce seeds that express apolipoprotein. This patent is key to successfully commercializing plant made and seed expressed Apo AI(Milano).
The intent of the Company's global patent strategy is to own exclusive rights to transgenic production of biosimilar drugs and novel drug candidates like Apo AI(Milano) in select plant and plant-seed lines and to be able to make such drugs in a scalable manner. In doing so, the Company believes it is rapidly becoming a highly attractive partner to large pharma partners looking to enter these markets with a differentiated and patent protected manufacturing cost structure.
A counterpart to the U.S. patent US 7,786,352 was issued in New Zealand and South Africa, and corresponding patents are pending in many jurisdictions worldwide including Europe, China, Japan, India, Eurasia, Brazil, Australia and Canada.
